- DNASTAR Extends Lasergene Site License Agreement with Memorial Sloan-Kettering Cancer Center
Industry News: DNASTAR Extends Lasergene Site License Agreement with Memorial Sloan-Kettering Cancer CenterDNASTAR, a leading bioinformatics software company, announced today the extension of a broad site license agreement with Memorial Sloan-Kettering Cancer Center for the use of Lasergene® sequence analysis software developed by DNASTAR.
Under the terms of the three year site license, Lasergene will continue to available to all researchers at the Center’s New York City location. Lasergene continues to be one of the leading DNA sequence analysis software packages commercially available and can be used on assembly and analysis applications for projects using both conventional and Next Generation Sequencing platforms.
Bob Steinhauser, DNASTAR’s Director of Sales Marketing, “Memorial Sloan-Kettering and DNASTAR first entered into a site license back in 2000. We are very pleased they chose to continue using our software for the majority of their sequence assembly and analysis research needs. Providing facility wide access to the same analysis software to simplify data sharing among their scientists is a continuing trend we see in our business. Lasergene’s novel features and regular upgrades to include new tools needed by the scientific community make it an excellent platform choice for organizations to base their future genomic research needs.”
Lasergene is a comprehensive, easy to use suite of tools for molecular biologists and geneticists used primarily in the assembly and analysis of DNA and protein sequences. The software provides researchers with a broad range of analysis tools that can be used with traditional and Next-Generation sequence analysis projects. It has been sold in over 65 countries worldwide and the Memorial Sloan-Kettering Cancer Center joins a growing list of public and private organizations that are utilizing the Lasergene sequence analysis software program.